Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis

Abstract

ObjectiveOur study aimed to evaluate the prognostic and clinicopathological significance of pretreatment mean platelet volume (MPV) on cancer by using meta-analysis of published studies.DesignMeta-analysis.Data sourcesRelevant studies available before 22 December 2019 were identified by searching MEDLINE, EMBASE.Eligibility criteriaAll published studies that assessed the prognostic and clinicopathological significance of pretreatment MPV on cancer were included.Data extraction and synthesisStudies were identified and extracted by two reviewers independently. The HR/OR and its 95% CIs of survival outcomes and clinicopathological parameters were calculated.ResultsA total of 38 eligible studies (41 subsets) with 9894 patients with cancer were included in the final meta-analysis. MPV level was not significantly associated with both overall survival (HR 0.98, 95% CI 0.84 to 1.14) and disease-free survival (HR 1.22, 95% CI 0.86 to 1.73) of patients with cancer. Neither advanced nor mixed-stage tumour patients showed significant association between MPV and overall survival (HR 1.36, 95% CI 0.96 to 1.94, HR 0.90, 95% CI 0.74 to 1.09). However, high MPV had the strongest relationship with poor overall survival (HR 2.01; 95% CI 1.08 to 3.41) in gastric cancer, followed by pancreatic cancer (HR 1.54; 95% CI 1.31 to 1.82). Whereas in the subgroup using receiver operating characteristic curve method to define cut-off values, low MPV was significantly related to poor overall survival (HR 0.78, 95% CI 0.64 to 0.95). In addition, MPV had no significant association with age (OR 0.96, 95% CI 0.90 to 1.02), sex (OR 1.04, 95% CI 1.00 to 1.09), depth of cancer invasion (OR 0.90, 95% CI 0.77 to 1.04) and tumour stage (OR 0.91, 95% CI 0.78 to 1.07).ConclusionsPretreatment MPV level is of no clearly prognostic significance in cancers and no significant association with clinicopathological parameters of patients with cancers.

Prognostic significance of mean platelet volume in lung cancer patients: A meta-analysis

“…While doing subgroup analysis including 7 studies, higher MPV levels were not associated with worse OS (NSCLC: HR 0.85, 95% CI 0.64 to 1.15). 14 Our study included 11 studies with NSCLC, SCLC, and NSCLC + SCLC, and similar to the above studies showed no statistically signi cant association.…”

Prognostic significance of mean platelet volume in patients with lung cancer: a meta-analysis

“…In a subgroup analysis of seven studies, higher MPV was not associated with worse OS in NSCLC (HR = 0.85, 95% CI = 0.64–1.15). 14 Our study included 11 studies of patients with NSCLC and/or SCLC, whereas nine studies including only patients with NSCLC were included in the meta-analysis to reduce bias. Similarly as the aforementioned studies, no significant association between MPV and outcomes was observed.…”

“…[7][8][9][10][11][12] However, the correlation between platelet count/ size and lung cancer prognosis remains controversial because some studies determined that MPV is a poor prognostic factor in NSCLC whereas others suggested that MPV has no association with lung cancer. 11,[13][14][15] Thus, a robust analysis investigating the prognostic value of MPV among patients with lung cancer is needed. We conducted a meta-analysis to comprehensively evaluate the prognostic significance of MPV in this malignancy.…”

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer

“…The underlying mechanism for the decreased MPV in patients with PCa is not clear for us. It has been suggested that the level of MPV depends on the intensity of the systemic inflammation ( 21 , 22 ). Mild system inflammation leads to platelet activation and enhanced release of larger platelets, therefore elevating MPV level.…”

“…Mild system inflammation leads to platelet activation and enhanced release of larger platelets, therefore elevating MPV level. While severe system inflammation was associated with low levels of MPV due to increased release rate of small size platelets and selective consumption of large amounts of highly reactive large-sized platelets ( 21 ). The relationship between systemic inflammatory response and prostate cancer had been reported ( 23 , 24 ).…”